(Q38126943)

29 August 2017

title

Chemotherapy for osteosarcoma - where does it come from? What is it? Where is it going? (English)

1 reference

29 August 2017

1 reference

2

Hiroyuki Tsuchiya

1 reference

29 August 2017

Norio Yamamoto

1

1 reference

29 August 2017

language of work or name

English

0 references

publication date

7 August 2013

1 reference

Expert Opinion on Pharmacotherapy

29 August 2017

published in

1 reference

29 August 2017

volume

14

1 reference

29 August 2017

issue

16

1 reference

29 August 2017

page(s)

2183-2193

1 reference

Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.827171

Extraskeletal osteosarcoma of penis: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.827171

The therapy of osteogenic sarcoma: Current status and thoughts for the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.827171

Primary osteogenic sarcoma. The rationale for preoperative chemotherapy and delayed surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.827171

Preoperative chemotherapy for osteogenic sarcoma:Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.827171

Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.827171

Effect of intraarterial versus intravenous cisplatin in addition to systemic doxorubicin, high-dose methotrexate, and ifosfamide on histologic tumor response in osteosarcoma (study COSS-86).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.827171

Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.827171

A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.827171

Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.827171

Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.827171

Ifosfamide and etoposide in childhood osteosarcoma. A phase II study of the French Society of Paediatric Oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.827171

High-dose ifosfamide in relapsed pediatric osteosarcoma: therapeutic effects and renal toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.827171

Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.827171

Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.827171

Multiinstitutional phase II study of neoadjuvant chemotherapy for osteosarcoma (NECO study) in Japan: NECO-93J and NECO-95J.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.827171

Phase II study of gemcitabine combined with oxaliplatin in relapsed or refractory paediatric solid malignancies: An innovative therapy for children with Cancer European Consortium Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.827171

Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children's oncology group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.827171

Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.827171

Comprehensive analysis of published phase I/II clinical trials between 1990-2010 in osteosarcoma and Ewing sarcoma confirms limited outcomes and need for translational investment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.827171

Caffeine enhancement of the effect of anticancer agents on human sarcoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.827171

Growth inhibition and differentiation of murine melanoma B16-BL6 cells caused by the combination of cisplatin and caffeine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.827171

In vitro enhancement of antitumor activity of a water-soluble duocarmycin derivative, KW-2189, by caffeine-mediated DNA-repair inhibition in human lung cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.827171

Caffeine and staurosporine enhance the cytotoxicity of cisplatin and camptothecin in human brain tumor cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.827171

Current concepts on the molecular biology of osteosarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.827171

Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.827171

Treatment of metastatic osteosarcoma with the somatostatin analog OncoLar: significant reduction of insulin-like growth factor-1 serum levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.827171

Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.827171

A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.827171

Analysis of biologic surrogate markers from a Children's Oncology Group Phase I trial of gefitinib in pediatric patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.827171

Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-Ommaya 131-I-3F8.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.827171

A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.827171

Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.827171

Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.827171

Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.827171

Phase I/II and phase II studies of targeted gene delivery in vivo: intravenous Rexin-G for chemotherapy-resistant sarcoma and osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.827171

Engineering targeted viral vectors for gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.827171

Molecular engineering of matrix-targeted retroviral vectors incorporating a surveillance function inherent in von Willebrand factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.827171

Rexin-G, a targeted genetic medicine for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.827171

Caffeine abolishes the mammalian G(2)/M DNA damage checkpoint by inhibiting ataxia-telangiectasia-mutated kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.827171

A role for ATR in the DNA damage-induced phosphorylation of p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.827171

Preoperative chemotherapy for stage IIIB extremity soft tissue sarcoma: long-term results from a single institution

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.827171

Radiographic response to neoadjuvant chemotherapy is a predictor of local control and survival in soft tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.827171

A randomised phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.827171

Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.827171

Chemoradiotherapy in the treatment of regional pancreatic carcinoma: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.827171

Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.827171

10.1517/14656566.2013.827171

21 January 2018

Identifiers

DOI

1 reference

29 August 2017

1 reference